What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Ophthalmic solution instilled directly into the eye (topical ocular administration)”In the company’s words, NCT07335211 on ClinicalTrials.gov
- Main trialPhase 3
- “A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension”In the company’s words, NCT07335211 on ClinicalTrials.gov
Other drugs for Primary Open Angle Glaucoma (POAG)
- Bimatoprost ophthalmic 0.01% YSBPYS Life Science Co., Ltd. · Phase 3
- Gen 2 Travoprost Intracameral ImplantGlaukos Corporation · Phase 3
- Product DNN.31.19.026Ache Laboratorios Farmaceuticos S.A. · Phase 3
- Citicoline eye drops 2%Omikron Italia S.r.l. · Phase 3
- Bimatoprost 0.01% OphthalmicAmneal Pharmaceuticals, LLC · Phase 3
- DE-117BSanten Pharmaceutical Co., Ltd. · Phase 3
Coming up1
- Nov 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Nov 2027 | Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026